Search research articles
Contact Us
Filters
Showing results (241-250 of 262) with videos related to
Page
of 27
Sort By:
The Lancet. Gastroenterology & Hepatology
|
May 10, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Shukui Qin, Qiu Li, Shanzhi Gu, et al.
The Lancet. Oncology
|
June 21, 2013
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Yi-Long Wu, Jin Soo Lee, Sumitra Thongprasert, et al.
Annals of Translational Medicine
|
January 7, 2016
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
Jun Guo, Shukui Qin, Jun Liang, et al.
European Journal of Medical Research
|
October 30, 2025
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study
Feng Bi, Shukui Qin, Shanzhi Gu, et al.
BMJ (Clinical Research Ed.)
|
May 28, 2024
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
Miao-Zhen Qiu, Do-Youn Oh, Ken Kato, et al.
Chinese Clinical Oncology
|
May 12, 2016
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
Jun Guo, Shukui Qin, Jun Liang, et al.
Signal Transduction and Targeted Therapy
|
June 16, 2025
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
Dan-Yun Ruan, Hao-Xiang Wu, Ye Xu, et al.
Nature Medicine
|
June 1, 2024
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
Feng Wang, Lin Shen, Weijian Guo, et al.
Journal of the National Cancer Center
|
July 22, 2024
Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer
Jiujie Cui, Feng Jiao, Qi Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
Shun Lu, Qiming Wang, Guojun Zhang, et al.
Page
of 27
Search research articles
Search
Showing results (241-250 of 262) with videos related to
Sort By:
Page
of 27
The Lancet. Gastroenterology & Hepatology
|
May 10, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Shukui Qin, Qiu Li, Shanzhi Gu, et al.
The Lancet. Oncology
|
June 21, 2013
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Yi-Long Wu, Jin Soo Lee, Sumitra Thongprasert, et al.
Annals of Translational Medicine
|
January 7, 2016
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
Jun Guo, Shukui Qin, Jun Liang, et al.
European Journal of Medical Research
|
October 30, 2025
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study
Feng Bi, Shukui Qin, Shanzhi Gu, et al.
BMJ (Clinical Research Ed.)
|
May 28, 2024
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
Miao-Zhen Qiu, Do-Youn Oh, Ken Kato, et al.
Chinese Clinical Oncology
|
May 12, 2016
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
Jun Guo, Shukui Qin, Jun Liang, et al.
Signal Transduction and Targeted Therapy
|
June 16, 2025
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
Dan-Yun Ruan, Hao-Xiang Wu, Ye Xu, et al.
Nature Medicine
|
June 1, 2024
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial
Feng Wang, Lin Shen, Weijian Guo, et al.
Journal of the National Cancer Center
|
July 22, 2024
Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer
Jiujie Cui, Feng Jiao, Qi Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
Shun Lu, Qiming Wang, Guojun Zhang, et al.
Page
of 27